Loading…
Dipna Pharmachem (BSE 543594)₹4.14−3.94%Pharmaceuticals
In the Mar 2026 quarter (standalone), Dipna Pharmachem reported sales of ₹2.04 Cr, down 87.2% from Mar 2025, and net profit of ₹0.19 Cr, down 62.7% year on year. For the year to Mar 2026, sales were ₹129 Cr and net profit ₹3.01 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 15.88 | 53.41 | 2.04 |
| Expenses | 14.66 | 51.91 | 1.60 |
| Operating Profit | 1.29 | 1.66 | 0.47 |
| OPM % | 8.1% | 3.1% | 22.5% |
| Other Income | 0.00 | 0.00 | 0.00 |
| Interest | 0.59 | 0.22 | 0.22 |
| Depreciation | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.69 | 1.43 | 0.24 |
| Tax % | 26.5% | 26.1% | 21.8% |
| Net Profit | 0.51 | 1.05 | 0.19 |
| EPS (Rs) | 0.20 | 0.39 | 0.06 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.95 | 19.96 | 29.92 | 30.93 | 72.89 | 99.83 | 164 | 125 | 129 |
| Expenses | 16.01 | 20.01 | 30.01 | 31.01 | 71.02 | 98.14 | 161 | 121 | 124 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 2.01 | 3.01 | 4.01 | 5.01 |
| OPM % | 2.4% | 2.4% | 1.5% | 1.3% | 3.0% | 2.4% | 2.1% | 3.0% | 3.9% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 1.99 | 1.99 | 0.99 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 1.01 | 1.01 | 1.01 | 4.01 |
| Tax % | 14.0% | 40.0% | 0.0% | 60.0% | 26.0% | 34.0% | 24.0% | 32.0% | 26.0% |
| Net Profit | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 3.01 |
| EPS (Rs) | 5.99 | 2.99 | 5.99 | 1.99 | 116.88 | 0.36 | 0.44 | 0.39 | 0.99 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 11.98 | 23.97 | 23.95 | 25.97 |
| Reserves | 0.00 | 0.00 | 0.99 | 0.99 | 1.99 | 11.97 | 12.98 | 13.98 | 35.96 |
| Borrowings | 5.01 | 6.02 | 10.03 | 12.03 | 10.03 | 16.04 | 19.05 | 17.05 | 13.04 |
| Other Liabilities | 6.01 | 8.02 | 8.01 | 12.02 | 24.07 | 37.10 | 76.16 | 77.20 | 130 |
| Total Liabilities | 11.01 | 14.03 | 18.02 | 25.03 | 36.08 | 78.09 | 133 | 132 | 206 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 11.01 | 14.03 | 18.02 | 25.03 | 36.08 | 78.09 | 133 | 132 | 206 |
| Inventories | 4.01 | 3.01 | 6.01 | 7.01 | 6.01 | 19.01 | 37.05 | 27.03 | 42.06 |
| Trade receivables | 5.99 | 8.99 | 10.99 | 14.98 | 26.99 | 28.99 | 30.98 | 45.98 | 47.97 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.99 | 13.96 | 0.00 | 0.99 |
| Total Assets | 11.01 | 14.03 | 18.02 | 25.03 | 36.08 | 78.09 | 133 | 132 | 206 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | −3.01 | −2.01 | 3.01 | −21.01 | −5.01 | −8.99 | −18.02 |
| Cash from investing activity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from financing activity | 2.99 | 1.99 | −2.99 | 25.97 | 13.99 | −3.99 | 18.99 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 5.01 | 8.03 | −13.04 | 0.00 |
| Capex | 0.00 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.05 |
| Free cash flow | −3.01 | −2.01 | 3.01 | −21.05 | −5.01 | −9.02 | −18.07 |
| CFO / OP % | −693.0% | −618.0% | 148.0% | −893.1% | −157.0% | −246.0% | −347.0% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 133 | 161 | 135 | 177 | 136 | 105 | 70 | 136 | 137 |
| Inventory days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 | 144 |
| Days payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 | 375 |
| Cash conversion cycle | 103 | 78 | 99 | 120 | 46 | 38 | −17 | −20 | −95 |
| Working capital days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 | 56 |
| ROCE % | — | 8.1% | 5.0% | 3.0% | 17.1% | 9.0% | 7.0% | 7.1% | 8.1% |
For the Mar 2026 quarter, Dipna Pharmachem reported sales of ₹2.04 Cr, down 87.2% year on year and net profit of ₹0.19 Cr, down 62.7% year on year. The operating margin was 22.5%.
Dipna Pharmachem's sales for the year to Mar 2026 were ₹129 Cr.
Net profit for the year to Mar 2026 was ₹3.01 Cr. Earnings per share over the same trailing period were ₹0.99.
Dipna Pharmachem reported borrowings of ₹13.04 Cr at Mar 2026, against cash and equivalents of ₹0.99 Cr.
Cash from operations was −₹18.02 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹18.07 Cr.